TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43

Research output: Chapter in Book/Report/Conference proceedingChapter

4 Citations (Scopus)

Abstract

The identification of TAR DNA-binding protein 43 (TDP-43) as the major disease protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin inclusions has defined a new class of neurodegenerative conditions: the TDP-43 proteinopathies. This breakthrough was quickly followed by mutation analysis of TARDBP, the gene encoding TDP-43. Herein, we provide a review of our previously published efforts that led to the identification of 3 TARDBP mutations (p.M337V, p.N345K, and p.I383V) in familial ALS patients, two of which were novel. With over 40 TARDBP mutations now discovered, there exists conclusive evidence that TDP-43 plays a direct role in neurodegeneration. The onus is now on researchers to elucidate the mechanisms by which mutant TDP-43 confers toxicity, and to exploit these findings to gain a better understanding of how TDP-43 contributes to the pathogenesis of disease. Our biochemical analysis of TDP-43 in ALS patient lymphoblastoid cell lines revealed a substantial increase in TDP-43 truncation products, including a ~25 kDa fragment, compared to control lymphoblastoid cell lines. We discuss the putative harmful consequence of abnormal TDP-43 fragmentation, as well as highlight additional mechanisms of toxicity associated with mutant TDP-43.

Original languageEnglish (US)
Title of host publicationAdvances in Alzheimer's Disease
Pages35-45
Number of pages11
Volume3
DOIs
StatePublished - 2012

Publication series

NameAdvances in Alzheimer's Disease
Volume3
ISSN (Print)22105727
ISSN (Electronic)22105735

Fingerprint

DNA-Binding Proteins
Mutation
Amyotrophic Lateral Sclerosis
Frontotemporal Lobar Degeneration
Cell Line
Ubiquitin
Research Personnel

Keywords

  • Amyotrophic lateral sclerosis
  • frontotemporal lobar degeneration
  • mutation
  • neurodegeneration
  • TARDBP
  • TDP-43

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43. / Gendron, Tania D; Rademakers, Rosa V; Petrucelli, Leonard.

Advances in Alzheimer's Disease. Vol. 3 2012. p. 35-45 (Advances in Alzheimer's Disease; Vol. 3).

Research output: Chapter in Book/Report/Conference proceedingChapter

@inbook{db40097d6e114fcbbdfada9010a31dfe,
title = "TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43",
abstract = "The identification of TAR DNA-binding protein 43 (TDP-43) as the major disease protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin inclusions has defined a new class of neurodegenerative conditions: the TDP-43 proteinopathies. This breakthrough was quickly followed by mutation analysis of TARDBP, the gene encoding TDP-43. Herein, we provide a review of our previously published efforts that led to the identification of 3 TARDBP mutations (p.M337V, p.N345K, and p.I383V) in familial ALS patients, two of which were novel. With over 40 TARDBP mutations now discovered, there exists conclusive evidence that TDP-43 plays a direct role in neurodegeneration. The onus is now on researchers to elucidate the mechanisms by which mutant TDP-43 confers toxicity, and to exploit these findings to gain a better understanding of how TDP-43 contributes to the pathogenesis of disease. Our biochemical analysis of TDP-43 in ALS patient lymphoblastoid cell lines revealed a substantial increase in TDP-43 truncation products, including a ~25 kDa fragment, compared to control lymphoblastoid cell lines. We discuss the putative harmful consequence of abnormal TDP-43 fragmentation, as well as highlight additional mechanisms of toxicity associated with mutant TDP-43.",
keywords = "Amyotrophic lateral sclerosis, frontotemporal lobar degeneration, mutation, neurodegeneration, TARDBP, TDP-43",
author = "Gendron, {Tania D} and Rademakers, {Rosa V} and Leonard Petrucelli",
year = "2012",
doi = "10.3233/978-1-61499-154-0-35",
language = "English (US)",
isbn = "9781614991533",
volume = "3",
series = "Advances in Alzheimer's Disease",
pages = "35--45",
booktitle = "Advances in Alzheimer's Disease",

}

TY - CHAP

T1 - TARDBP mutation analysis in TDP-43 proteinopathies and deciphering the toxicity of mutant TDP-43

AU - Gendron, Tania D

AU - Rademakers, Rosa V

AU - Petrucelli, Leonard

PY - 2012

Y1 - 2012

N2 - The identification of TAR DNA-binding protein 43 (TDP-43) as the major disease protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin inclusions has defined a new class of neurodegenerative conditions: the TDP-43 proteinopathies. This breakthrough was quickly followed by mutation analysis of TARDBP, the gene encoding TDP-43. Herein, we provide a review of our previously published efforts that led to the identification of 3 TARDBP mutations (p.M337V, p.N345K, and p.I383V) in familial ALS patients, two of which were novel. With over 40 TARDBP mutations now discovered, there exists conclusive evidence that TDP-43 plays a direct role in neurodegeneration. The onus is now on researchers to elucidate the mechanisms by which mutant TDP-43 confers toxicity, and to exploit these findings to gain a better understanding of how TDP-43 contributes to the pathogenesis of disease. Our biochemical analysis of TDP-43 in ALS patient lymphoblastoid cell lines revealed a substantial increase in TDP-43 truncation products, including a ~25 kDa fragment, compared to control lymphoblastoid cell lines. We discuss the putative harmful consequence of abnormal TDP-43 fragmentation, as well as highlight additional mechanisms of toxicity associated with mutant TDP-43.

AB - The identification of TAR DNA-binding protein 43 (TDP-43) as the major disease protein in amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with ubiquitin inclusions has defined a new class of neurodegenerative conditions: the TDP-43 proteinopathies. This breakthrough was quickly followed by mutation analysis of TARDBP, the gene encoding TDP-43. Herein, we provide a review of our previously published efforts that led to the identification of 3 TARDBP mutations (p.M337V, p.N345K, and p.I383V) in familial ALS patients, two of which were novel. With over 40 TARDBP mutations now discovered, there exists conclusive evidence that TDP-43 plays a direct role in neurodegeneration. The onus is now on researchers to elucidate the mechanisms by which mutant TDP-43 confers toxicity, and to exploit these findings to gain a better understanding of how TDP-43 contributes to the pathogenesis of disease. Our biochemical analysis of TDP-43 in ALS patient lymphoblastoid cell lines revealed a substantial increase in TDP-43 truncation products, including a ~25 kDa fragment, compared to control lymphoblastoid cell lines. We discuss the putative harmful consequence of abnormal TDP-43 fragmentation, as well as highlight additional mechanisms of toxicity associated with mutant TDP-43.

KW - Amyotrophic lateral sclerosis

KW - frontotemporal lobar degeneration

KW - mutation

KW - neurodegeneration

KW - TARDBP

KW - TDP-43

UR - http://www.scopus.com/inward/record.url?scp=84877941235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877941235&partnerID=8YFLogxK

U2 - 10.3233/978-1-61499-154-0-35

DO - 10.3233/978-1-61499-154-0-35

M3 - Chapter

SN - 9781614991533

VL - 3

T3 - Advances in Alzheimer's Disease

SP - 35

EP - 45

BT - Advances in Alzheimer's Disease

ER -